

Copper(I)-Catalyzed Cycloaddition of 4-Bromo-Sydnones and Alkynes for the Regioselective Synthesis of 1,4,5-Trisubstituted Pyrazoles.

Elodie Decuypere, Simon Specklin, Sandra Gabillet, Davide Audisio, Hui Liu, Lucie Plougastel, Sergii Kolodych, Frédéric Taran*

Service de Chimie Bioorganique et de Marquage and Service de Chimie Moléculaire, Commissariat à l'Energie Atomique, Gif Sur Yvette, F-91191 France.

frederic.taran@cea.fr

Supporting Information

Table of Contents


Synthesis and analytical data of ligands L9-L12	p 2
Procedure and analytical data of 5-bromopyrazoles 3	p 5
Optimization of Suzuki coupling of 5-bromopyrazoles 3	p 14
Procedure and analytical data of 1,4,5-trisubstituted pyrazoles 6	p 14
Mechanism study of the CuSAC reaction	p18
NMR Spectra of compounds	p 22

General

Organic solvents (Aldrich) were used without further purification. Purifications of reactions products were carried out by flash chromatography using Merck silica gel (40–63 μm). Infrared spectra (IR) were obtained on a Perkin Elmer UATR TWO FTIR spectrophotometer and are reported as wavelength numbers (cm^{-1}). Infrared spectra prepared with a KBr or NaCl pellet containing the title compound were obtained on a Perkin Elmer system 2000 FTIR spectrophotometer. ^1H NMR (400 MHz), ^{13}C NMR (100 MHz) were measured on a Bruker Avance 400 MHz spectrometer. Chemical shifts are reported in parts per million (ppm, δ) downfield from residual solvents peaks and coupling constants are reported as Hertz (Hz). Splitting patterns are designated as singlet (s), doublet (d), triplet (t), Splitting patterns that could not be interpreted or easily visualized are designated as multiplet (m). Electrospray mass spectra were obtained using an ESI/TOF Mariner Mass Spectrometer. High resolution mass spectra were obtained using a LCT PREMIER/XE WATERS TOF. Isotopic enrichments were calculated using direct injection ESI mass spectrometer. Unless otherwise noted, all other commercially available reagents and solvents were used without further purification.


Synthesis and analytical data of ligands L9-L12

Ligands **L9-L12** were synthesised according to a described synthetic route (scheme S1).¹



Scheme S1. General route to ligands L9-12

- 1-[2-(1H-imidazol-1-yl)phenyl]-1H-imidazole (**L0**)




In a round-bottom flask were added 1,2-dibromobenzene (10.0 g, 42.4 mmol), imidazole (7.21 g, 106 mmol), K_2CO_3 (11.7 g, 84.8 mmol), Cu_2O (0.303 g, 2.12 mmol), and DMSO (20 mL). The mixture was stirred at 150 $^\circ\text{C}$ overnight. The resultant mixture was cooled to room temperature and filtered off through Celite with EtOAc. To the organic solution was added H_2O and the mixture was extracted with EtOAc. The combined organic layer were dried over MgSO_4 and evaporated under vacuum. A recrystallisation was performed with CHCl_3 and heptane to give 3.30 g of compound **L0** (white powder) with 45% yield.

^1H NMR (CDCl_3 , 400MHz): $\delta = 7.53\text{--}7.60$ (m, 2 H), $7.46\text{--}7.52$ (m, 2 H), $7.41\text{--}7.46$ (m, 2 H), 7.11 (s, 2 H), 6.74 (s, 2 H) ppm ;

¹Matsumoto, S., Batmunkh, E., Akazome, M., Takata, Y., Tamano, M. *Org. Bio. Chem.* **2011**, 9, 5941.

¹³C NMR (CDCl₃, 101MHz): δ = 136.7 (2C), 132.1 (2C), 130.5 (2C), 129.7 (2C), 127.1 (2C), 119.4 (2C) ppm ;
IR (NaCl, cm⁻¹) : 3101, 2919, 2850, 1682, 1600, 1520, 1487, 1368, 1304, 1247, 1177, 1112, 1090, 1065, 965, 904, 835, 780 ;
MS (ESI) *m/z* : 211 [M+H]⁺.

- diimidazo[1,2-a:2',1'-c]quinoxaline (**L9**)



M = 208.07 g/mol
 C₁₂H₈N₄


L0 (400 mg, 1.90 mmol) was dissolved in 8 mL of dried THF. The reaction was cooled to -78 °C and BuLi (1.6 M solution, 2.85 mL) was added dropwise. The reaction mixture was stirred for 60 min, then a solution of Pd(PPh₃)₄ (43.9 mg, 0.0380 mmol) in THF (5 mL) was added. The solution was slowly warmed to room temperature, and stirred for 19 h under argon atmosphere. Then a solution of brine was added and extraction was carried out with ethyl acetate. The organic layer was dried with magnesium sulfate, and then evaporated under vacuum. A recrystallization was performed in CHCl₃ and heptane to give 341 mg of compound **L9** (bright yellow powder) in 86% yield.

¹H NMR (CDCl₃, 400MHz): δ = 7.89–7.66 (m, 4 H), 7.628–7.625 (m, 2 H), 7.55–7.53 (m, 2 H) ppm ;
¹³C NMR (CDCl₃, 101MHz): δ = 135.8 (2C), 132.6 (2C), 126.3 (2C), 124.4 (2C), 116.6 (2C), 112.4 (2C) ppm ;
IR (NaCl, cm⁻¹) : 1633, 1574, 1509, 1463, 1410, 1348, 1326, 1116, 931, 759, 685 ;
MS (ESI) *m/z* : 231 [M+Na]⁺.

General Procedure A for arylation of compound **L9**:

Into a round bottom flask, dried K₂CO₃ (4 equiv.), **L9** (1 equiv.), bromoaryl (3 equiv.), Pd(OAc)₂ (0.1 equiv.) and dppe (0.2 equiv.) were mixed in DMF (final concentration 0.1 M). The mixture was stirred at 140 °C for 48 h under argon atmosphere. The resultant mixture was cooled down to room temperature and subsequently filtered off through celite with CHCl₃ three times. To the organic solution was added brine. The combined mixture was extracted with CHCl₃. The combined organic layers were dried over magnesium sulfate and evaporated. A column chromatography was performed (EtOAc/Heptane : 9/1).

- 3,10-bis(4-nitrophenyl)diimidazo[1,2-a:2',1'-c]quinoxaline (**L10**)



M = 450.41 g/mol
 C₂₄H₁₄N₆O₄

Compound **L10** was obtained in 59% yield, 127 mg (orange solid) from compound **L9** (100 mg, 0.48 mmol), 1-bromo-4-nitrobenzene (388 mg, 1.92 mmol), using general procedure **A** and purified by column chromatography (Heptane/ Ethyl acetate : 1/9).

Mp : decomp. > 315 °C ;


¹H NMR (CDCl₃, 400MHz): δ = 8.42 (d, *J* = 8.4 Hz, 4 H), 7.79 (d, *J* = 8.4 Hz, 4 H), 7.68 (s, 2 H), 7.49–7.47 (m, 2 H), 7.22–7.20 (m, 2 H) ppm ;

¹³C NMR (CDCl₃, 101MHz): δ = 147.8 (2C), 138.3 (2C), 136.5 (2C), 135.6 (2C), 129.5 (4C), 128.4 (2C), 126.1 (2C), 125.6 (2C), 124.5 (4C), 118.9 (2C) ppm ;

IR (ν, cm⁻¹): 3102, 1916, 1596, 1515, 1492, 1474, 1375, 1342, 1299, 1139, 1108, 1014, 973, 909, 852, 753, 731, 697 ;

MS (ESI) *m/z* : 451 [M+H]⁺.

- 3,10-diphenyldiimidazo[1,2-a:2',1'-c]quinoxaline (**L11**)



M = 360.14 g/mol
C₂₄H₁₆N₄

Compound **L11** was obtained in 84% yield, 400 mg (yellow solid) from compound **L9** (275 mg, 1.32 mmol) and bromobenzene (416 μL, 3.96 mmol), using general procedure **A** and purified by column chromatography (Heptane/ Ethyl acetate : 1/9).

Mp : 219–221 °C


¹H NMR (CDCl₃, 400MHz): δ = 7.45–7.59 (m, 14 H), 6.99–7.07 (m, 2 H) ppm ;

¹³C NMR (CDCl₃, 101MHz): δ = 137.2 (2C), 133.6 (2C), 130.6 (2C), 130.2 (2C) , 129.6 (4C), 129.1 (6C), 126.0 (2C), 125.2 (2C), 118.5 (2C) ppm

IR (ν, cm⁻¹): 3057, 1708, 1623, 1572, 1523, 1494, 1476, 1445, 1376, 1347, 1283, 1161, 1073, 953, 848, 761, 731, 702, 645 ;

MS (ESI) *m/z* : 361 [M+H]⁺.

- 3,10-bis(4-methoxyphenyl)diimidazo[1,2-a:2',1'-c]quinoxaline (**L12**)



M = 420.16 g/mol
C₂₆H₂₀N₄O₂

Compound **L12** was obtained in 40% yield, 82 mg (brown solid) from compound **L9** (100 mg, 0.48 mmol) and bromoanisole (240 μL, 1.92 mmol), using general procedure **A** and purified by column chromatography (Heptane/ Ethyl acetate : 1/9).

Mp : 189–191 °C

¹H NMR (CDCl₃, 400MHz): δ = 7.53– 7.51 (m, 3 H), 7.46–7.43 (m, 5 H), 7.05–7.03 (m, 6 H), 3.51 (s, 6 H) ppm ;

¹³C NMR (CDCl₃, 400MHz): δ = 160.2 (2C), 136.9 (2C), 133.3 (2C), 131.1 (4C), 129.8 (2C), 126.2 (2C), 125.1 (2C), 122.8 (2C), 118.3 (2C), 114.5 (4C), 55.6 (2C) ppm ;

IR (ν, cm⁻¹): 3004, 2960, 2838, 2545, 2231, 2045, 1894, 1681, 1610, 1573, 1556, 1505, 1494, 1473, 1463, 1441, 1416, 1376, 1347, 1297, 1249, 1177, 1109, 1083, 1029, 954, 909, 8333, 754, 731, 678 ;

MS (ESI) *m/z* : 421 [M+H]⁺.

Synthesis and analytical data of 5-bromopyrazoles:

Sydnones were synthesized according to our previously described procedure.²


General procedure B:

To a solution of sydnone (1 equiv.) in acetone, NBS (1.2 equiv.) was added. The reaction mixture was stirred 2h and acetone was removed by evaporation under vacuum. To the latter flask containing the bromosydnone a solution of alkyne (1.2 equiv.) and sodium ascorbate (2 equiv.) in *tert*-butanol/water (55/45) were added a freshly prepared aqueous solution of CuSO₄·5H₂O (0.2 equiv., 0.1 M final concentration), ligand (0.2 equiv., 0.1 M final concentration) and triethanolamine (1 equiv., 0.5 M final concentration). The reaction mixture was stirred at 60 °C overnight. Afterwards the reaction mixture was quenched with an aqueous solution of HEDTA (0.05 M) and extracted with dichloromethane. The organic layer were combined, dried over anhydrous magnesium sulfate and evaporated under vacuum. The crude mixture was purified by column chromatography.

General Procedure C:

To a solution of sydnone (1 equiv.) in acetone, NBS (1.2 equiv.) was added. The reaction mixture was stirred 2h and acetone was removed by evaporation under vacuum. To the latter flask containing bromosydnone a solution of alkyne (1.2 equiv.) and sodium ascorbate (2 equiv.) in *tert*-butanol/water (55/45) were added in four subsequent equal portions a freshly prepared aqueous solution of CuSO₄·5H₂O (0.2 equiv., 0.1 M final concentration), ligand (0.2 equiv., 0.1 M final concentration) and triethanolamine (1 equiv., 0.5 M final concentration) every 2 hours. The reaction mixture was stirred at 60 °C overnight. Afterwards the reaction mixture was quenched with an aqueous solution of HEDTA (0.05 M) and extracted with dichloromethane. The organic layer were combined, dried over anhydrous magnesium sulfate and evaporated under vacuum. The crude mixture was purified by column chromatography.

- 5-bromo-4-phenethyl-1-phenyl-1H-pyrazole (**3a**)



Compound **3a** was obtained in 74% yield, 111 mg (yellow solid) from 3-phenyl-4-bromo-sydnone (110.8 mg, 0.46 mmol) using general procedure **B** and purified by column chromatography (Heptane/Ethyl acetate : 95/5).

¹H NMR (CDCl₃, 400MHz): δ = 7.38–7.55 (m, 6 H), 7.28–7.34 (m, 2 H), 7.19–7.25 (m, 3 H), 2.89–2.95 (m, 2 H), 2.77–2.83 (m, 2 H) ppm ;

¹³C NMR (CDCl₃, 101MHz): δ = 141.4, 140.9, 139.4, 129.0, 128.6, 128.6, 128.3, 126.3, 125.6, 122.3, 112.6, 36.3, 26.7 ppm ;


IR (NaCl, cm⁻¹) : 3062, 3027, 2923, 2856, 1598, 1556, 1499, 1455, 1407, 1391, 1241, 1087, 1068, 961, 911, 851, 836, 760, 694 ;

MS (ESI) *m/z* : 327 [M(⁷⁹Br) + H]⁺, 329 [M(⁸¹Br) + H]⁺ ;

HRMS (ESI) *m/z* calcd for C₁₇H₁₆N₂Br [M+H] + (79Br): 327.0497; found: 327.0499.

² S. Specklin, E. Decuypere, L. Plougastel, S. Aliani, F. Taran. *J. Org. Chem.* **2014**, 79 (16), 7772–7777

- 5-bromo-1-(4-methylphenyl)-4-(2-phenylethyl)-1H-pyrazole (**3b**)



M = 341.25 g/mol
C₁₈H₁₇BrN₂

Compound **3b** was obtained in 80% yield, 85 mg (yellow solid) from 3-tolyl-4-bromo-sydnone (74.7 mg, 0.31 mmol) using general procedure **C** and purified by column chromatography (Heptane/ Ethyl acetate : 95/5).

Mp : 114–116 °C ;

¹H NMR (CDCl₃, 400MHz): δ = 7.50 (s, 1 H), 7.4 (d, *J* = 8.5 Hz, 2 H), 7.33–7.28 (m, 4 H), 7.24–7.20 (m, 3 H), 2.96–2.90 (m, 2 H), 2.81–2.77 (m, 2 H), 2.42 (s, 3 H) ppm ;


¹³C NMR (CDCl₃, 101MHz): δ = 141.2, 140.4, 138.2, 136.8, 129.4 (2C), 128.4 (2C), 128.3 (2C), 126.0, 125.3 (2C), 121.8, 112.5, 36.1, 26.5, 21.1 ppm ;

IR (ν, cm⁻¹): 3026, 2922, 2858, 1603, 1516, 1496, 1453, 1390, 1241, 1077, 961, 904, 818, 724, 697, 650 ;

MS (ESI) *m/z* : 341 [M(⁷⁹Br) + H]⁺, 343 [M(⁸¹Br) + H]⁺ ;

HRMS (ESI) *m/z* calcd for C₁₈H₁₈N₂Br [M+H]⁺ (⁷⁹Br): 341.0653; found: 341.0648.

- 5-bromo-1-(4-methoxyphenyl)-4-(2-phenylethyl)-1H-pyrazole (**3c**)



M = 357.24 g/mol
C₁₈H₁₇BrN₂O

Compound **3c** was obtained in 70% yield, 78 mg (yellow solid) from 3-(*p*-methoxy-phenyl)-4-bromo-sydnone (84.0 mg, 0.31 mmol) using general procedure **B** and purified by column chromatography (Heptane/ Ethyl acetate : 95/5).

Mp : 139-141 °C

¹H NMR (CDCl₃, 400MHz): δ = 7.49 (s, 1 H), 7.39–7.44 (m, 2 H), 7.28–7.34 (m, 2 H), 7.19–7.25 (m, 3 H), 6.95–7.01 (m, 2 H), 3.86 (s, 3 H), 2.88–2.95 (m, 2 H), 2.75–2.82 (m, 2 H) ppm ;


¹³C NMR (CDCl₃, 101MHz): δ = 159.4, 141.3, 140.3, 132.4, 128.6 (2C), 128.4 (2C), 127.0 (2C), 126.1, 121.7, 114.0 (2C), 112.9, 55.6, 36.1, 26.7 ppm ;

IR (ν, cm⁻¹) : 3004, 2911, 2634, 1609, 1588, 1512, 1493, 1453, 1440, 1395, 1302, 1244, 1174, 1149, 1110, 1029, 960, 853, 834, 800, 765, 748, 719, 667, 654 ;

MS (ESI) *m/z* : 357 [M(⁷⁹Br) + H]⁺, 359 [M(⁸¹Br) + H]⁺ ;

HRMS (ESI) *m/z* calcd for C₁₈H₁₈N₂OBr [M+H]⁺ (⁷⁹Br): 357.0602; found: 357.0601.

- 5-bromo-1-(4-fluorophenyl)-4-(2-phenylethyl)-1H-pyrazole (**3d**)



M = 345.22 g/mol
C₁₇H₁₄BrFN₂

Compound **3d** was obtained in 55% yield, 59 mg (yellow solid) from 3-(*p*-fluoro-phenyl)-4-bromo-sydnone (74.7 mg, 0.31 mmol) using general procedure **C** and purified by column chromatography (Heptane/ Ethyl acetate : 95/5).

Mp : 120–122 °C ;

¹H NMR (CDCl₃, 400MHz): δ = 7.52–7.49 (m, 3 H), 7.33–7.30 (m, 2 H), 7.24–7.22 (m, 3 H), 7.19–7.14 (m, 2 H), 2.94–2.90 (m, 2 H), 2.82–2.78 (m, 2 H) ppm ;


¹³C NMR (CDCl₃, 101MHz): δ = 162.1 (d, *J*_{C-F} = 247 Hz, 1C), 141.1, 140.1, 135.4 (d, *J*_{C-F} = 3.1 Hz, 1C), 128.43 (2C), 128.37 (2C), 127.3 (d, *J*_{C-F} = 8.5 Hz, 2C), 126.1, 122.3, 115.8 (d, *J*_{C-F} = 23.1 Hz, 2C), 112.6, 36.0, 26.5 ppm ;

IR (ν, cm⁻¹): 3061, 3024, 2921, 2852, 1740, 1604, 1512, 1453, 1394, 1290, 1231, 1151, 1098, 1078, 1028, 1012, 963, 836, 817, 752, 735, 718, 653 ;

MS (ESI) *m/z* : 345 [M(⁷⁹Br) + H]⁺, 347 [M(⁸¹Br) + H]⁺ ;

HRMS (ESI) *m/z* calcd for C₁₇H₁₄BrFN₂ [M+H]⁺ (⁷⁹Br): 345.0403; found: 345.0400.

- 5-bromo-1-(4-iodophenyl)-4-(2-phenylethyl)-1H-pyrazole (**3e**)



M = 453.11 g/mol
C₁₇H₁₄BrIN₂

Compound **3e** was obtained in 72% yield, 101 mg (yellow solid) from 3-(*p*-iodo-phenyl)-4-bromo-syndnone (113.8 mg, 0.31 mmol) using general procedure **B** and purified by column chromatography (Heptane/ Ethyl acetate : 95/5).

Mp : 108–110 °C ;


¹H NMR (CDCl₃, 400MHz): δ = 7.8 (d, *J* = 7.3 Hz, 2 H), 7.5 (s, 1 H), 7.33–7.29 (m, 4H), 7.24–7.21 (m, 3 H), 2.93–2.89 (m, 2 H), 2.82–2.78 (m, 2 H) ppm;

¹³C NMR (CDCl₃, 101MHz): δ = 141.1, 141.0, 138.9, 137.9 (2C), 128.41 (2C), 128.37 (2C), 126.9 (2C), 126.1, 125.6, 112.2, 93.3, 35.9, 26.5 ppm;

IR (ν, cm⁻¹) : 3086, 3026, 2923, 2857, 1603, 1586, 1495, 1454, 1387, 1303, 1240, 1055, 1009, 959, 824, 740, 698 ;

MS (ESI) *m/z* : 454 [M(⁷⁹Br) + H]⁺, 456 [M(⁸¹Br) + H]⁺.

- ethyl 5-bromo-1-phenyl-1H-pyrazole-4-carboxylate (**3f**)



M = 295.14 g/mol
C₁₂H₁₁BrN₂O₂

Compound **3f** was obtained in 38% yield, 35 mg (white solid) from 3-phenyl-4-bromo-syndnone (74.7 mg, 0.31 mmol) using general procedure **C** and purified by column chromatography (Heptane/ Ethyl acetate : 95/5).

Mp :86-88 °C ;

¹H NMR (CDCl₃, 400MHz): δ = 8.14 (s, 1 H), 7.53–7.94 (m, 5 H), 4.37 (q, *J* = 7.2 Hz, 2 H), 1.4 (t, *J* = 7.2 Hz, 3 H) ppm ;


¹³C NMR (CDCl₃, 101MHz): δ = 161.7, 143.1, 138.3, 129.2, 129.0 (2C), 126.1 (2C), 117.8, 115.1, 60.5, 14.3 ppm ;

IR (ν, cm⁻¹): 2981, 1713, 1597, 1530, 1499, 1458, 1399, 1372, 1296, 1238, 1222, 1171, 1066, 1047, 955, 904, 833, 762, 727, 692, 650 ;

MS (ESI) *m/z* : 295 [M(⁷⁹Br) + H]⁺, 297 [M(⁸¹Br) + H]⁺ ;

HRMS (ESI) *m/z* calcd for C₁₂H₁₁BrN₂O₂ [M+H]⁺ (⁷⁹Br): 295.0082; found: 295.0076.

- 5-bromo-1,4-diphenyl-1H-pyrazole (**3g**)



M = 299.17 g/mol
C₁₅H₁₁BrN₂

Compound **3g** was obtained in 63% yield, 58 mg (yellow solid) from 3-phenyl-4-bromo-sydnone (74.7 mg, 0.31 mmol) using general procedure **B** and purified by column chromatography (Heptane/Ethyl acetate : 95/5).

Mp: 161–163 °C ;

¹H NMR (CDCl₃, 400MHz): δ = 7.89 (s, 1 H), 7.65–7.63 (m, 2 H), 7.61–7.58 (m, 2 H), 7.54–7.50 (m, 2 H), 7.48–7.44 (m, 3 H) ppm ;


¹³C NMR (CDCl₃, 101MHz): δ = 140.4, 139.1, 131.4, 129.4, 128.9 (2C), 128.6 (2C), 127.7 (2C), 127.3, 125.9 (2C), 125.7, 119.0 ppm ;

IR (ν, cm⁻¹) : 2920, 1768, 1597, 1553, 1499, 1385, 1073, 981, 945, 862, 756, 717, 693, 642 ;

MS (ESI) *m/z* : 299 [M(⁷⁹Br) + H]⁺, 301 [M(⁸¹Br) + H]⁺ ;

HRMS (ESI) *m/z* calcd for C₁₅H₁₂N₂Br [M+H]⁺ (⁷⁹Br): 299.0184; found: 299.0193.

- 5-bromo-4-(6-methoxynaphthalen-2-yl)-1-phenyl-1H-pyrazole (**3h**)



M = 379.26 g/mol
C₂₀H₁₅BrN₂O

Compound **3h** was obtained in 77% yield, 91 mg (white solid) from 3-phenyl-4-bromo-sydnone (74.7 mg, 0.31 mmol) using general procedure **C** and purified by column chromatography (Heptane/Ethyl acetate : 95/5).

Mp : 145–147 °C

¹H NMR (CDCl₃, 400MHz): δ = 8.03 (s, 1 H), 7.98 (s, 1 H), 7.83–7.78 (m, 2 H), 7.71 (dd, *J* = 1.3 Hz, *J* = 8.4 Hz, 1 H), 7.62 (d, *J* = 7.9 Hz, 2 H), 7.55–7.45 (m, 3 H), 7.20–7.17 (m, 2 H), 3.95 (s, 3 H) ppm ;


¹³C NMR (CDCl₃, 101MHz): δ = 157.9, 140.6, 139.2, 133.7, 129.5, 129.0 (2C), 128.6, 127.1, 126.6, 126.4, 126.3, 126.0 (2C), 123.6, 119.2, 111.3, 105.7, 55.4 ppm ;

IR (ν, cm⁻¹): 3053, 2955, 1773, 2629, 1597, 1499, 1479, 1386, 1359, 1262, 1218, 1198, 1165, 1026, 961, 903, 890, 851, 843, 756, 694, 654, 533, 476 ;

MS (ESI) *m/z* : 379 [M(⁷⁹Br) + H]⁺, 381 [M(⁸¹Br) + H]⁺ ;

HRMS (ESI) *m/z* calcd for C₂₀H₁₆N₂OBr [M+H]⁺ (⁷⁹Br): 379.0446; found: 379.0446.

- 5-bromo-4-(4-methoxyphenyl)-1-phenyl-1H-pyrazole (**3i**)



M = 329.20 g/mol
C₁₆H₁₃BrN₂O

Compound **3i** was obtained in 44% yield, 45 mg (yellow solid) from 3-phenyl-4-bromo-sydnone (74.7 mg, 0.31 mmol) using general procedure **D** and purified by column chromatography (Heptane/Ethyl acetate : 95/5).

Mp : 174–176 °C ;

¹H NMR (CDCl₃, 400MHz): δ = 7.85 (s, 1 H), 7.60–7.45 (m, 7 H), 6.99 (d, *J* = 8.5 Hz, 2 H), 3.86 (s, 3 H) ppm ;


¹³C NMR (CDCl₃, 101MHz): δ = 158.9, 140.2, 139.2, 128.92 (2C), 128.87 (2C), 128.7, 128.5, 125.9 (2C), 123.8, 123.2, 114.1 (2C), 55.3 ppm ;

IR (ν, cm⁻¹) : 2952, 1598, 1556, 1497, 1456, 1396, 1366, 1306, 1283, 1252, 1180, 1112, 1070, 1031, 948, 907, 835, 756, 730, 693, 645 ;

MS (ESI) *m/z* : 329 [M(⁷⁹Br) + H]⁺, 331 [M(⁸¹Br) + H]⁺ ;

HRMS (ESI) *m/z* calcd for C₁₆H₁₄N₂OBr [M+H]⁺ (⁷⁹Br): 329.0289; found: 329.0294.

- tert-butyl N-[(5-bromo-1-phenyl-1H-pyrazol-4-yl)methyl]carbamate (**3j**)



M = 352.23 g/mol
C₁₅H₁₈BrN₃O₂

Compound **3j** was obtained in 69% yield, 75 mg (yellow solid) from 3-phenyl-4-bromo-syndnone (74.7 mg, 0.31 mmol) using general procedure **C** and purified by column chromatography (Heptane/ Ethyl acetate : 95/5).

Mp : 11–113 °C ;


¹H NMR (CDCl₃, 400MHz): δ = 7.74 (s br., 1 H), 7.56–7.38 (m, 5 H), 4.84 (s br., 1 H), 4.22 (d, *J* = 4.0 Hz, 2 H), 1.47 (s, 9 H) ppm ;

¹³C NMR (CDCl₃, 101MHz): δ = 155.6, 140.9, 138.9, 128.9 (2C), 128.4, 125.4 (2C), 120.2, 112.5, 79.6, 35.3, 28.4 (3C) ppm ;

IR (ν, cm⁻¹) : 3355, 2985, 1689, 1598, 1523, 1499, 1388, 1366, 1344, 1275, 1247, 1166, 1140, 1087, 1064, 1043, 1026, 963, 914, 812, 755, 692, 645 ;

MS (ESI) *m/z* : 374 [M(⁷⁹Br) + Na]⁺, 376 [M(⁸¹Br) + Na]⁺.

- (5-bromo-1-phenyl-1H-pyrazol-4-yl)methyl benzoate (**3k**)



M = 357.21 g/mol
C₁₇H₁₃BrN₂O₂

Compound **3k** was obtained in 52% yield, 58 mg (white solid) from 3-phenyl-4-bromo-syndnone (74.7 mg, 0.31 mmol) using general procedure **B** and purified by column chromatography (Heptane/ Ethyl acetate : 95/5)

Mp : 111–113 °C

¹H NMR (CDCl₃, 400MHz): δ = 8.08 (d, *J* = 7.3 Hz, 2 H), 7.88 (s, 1 H), 7.58–7.42 (m, 8 H), 5.30 (s, 2 H) ppm ;


¹³C NMR (CDCl₃, 101MHz): δ = 166.4, 141.9, 138.8, 133.0, 129.9, 129.7 (2C), 128.9 (2C), 128.6, 128.3 (2C), 125.6 (2C), 117.9, 114.7, 57.5 ;

IR (ν, cm⁻¹): 3059, 2922, 1713, 1595, 1556, 1498, 1541, 1404, 1385, 1343, 1314, 1178, 1103, 1069, 1025, 960, 951, 851, 767, 751, 710, 697, 690, 649, 551 ;

MS (ESI) *m/z* : 357 [M(⁷⁹Br) + H]⁺, 359 [M(⁸¹Br) + H]⁺ ;

HRMS (ESI) *m/z* calcd for C₁₇H₁₄N₂O₂Br [M+H]⁺ (⁷⁹Br): 357.0239; found: 357.0255.

- **5-(4H-sydnone)quinoline**



M = 213.2 g/mol
C₁₁H₇N₃O₂

5-(4H-sydnone)quinoline was obtained in 71 % yield, 74 mg (red solid) according our previously described procedure using 5-aminoquinoline (100 mg, 0.49 mmol), tert-butylnitrite (65 μ L, 0.54 mmol) and trifluoroacetic acid (173 μ L, 1.23 mmol) and purified by column chromatography (Dichloromethane/Ethyl acetate : 4/6).³

Mp : 172–173 °C ;


¹H NMR (CDCl₃, 400MHz): 9.10 (d br., *J* = 3.6 Hz, 1 H), 8.45 (d, *J* = 8.5 Hz, 1 H), 8.17 (d, *J* = 8.5 Hz, 1 H), 7.93–7.87 (m, 1 H), 7.83–7.81 (m, 1 H), 7.62 (dd, *J* = 4.3, 8.5 Hz, 1 H), 6.61 (s, 1 H) ppm ;

¹³C NMR (CDCl₃, 101MHz): 168.4, 152.2, 148.1, 134.5, 130.6, 129.6, 128.3, 123.7, 123.6, 122.4, 98.1 ppm ;

IR (ν , cm⁻¹): 3104, 1775, 1620, 1596, 1567, 1506, 1423, 1346, 1317, 1249, 1208, 1183, 1170, 1122, 1068, 1029, 971, 937, 870, 826, 801, 727, 644 ;

MS (ESI) *m/z* : 214 [M + H]⁺.

- **5-(5-bromo-4-phenethyl-1H-pyrazol-1-yl)quinoline (3l)**



M = 377,05 g/mol
C₂₀H₁₆BrN₃

Compound **3l** was obtained in 33% yield, 37 mg (red oil) from 4-bromo-sydnone-5-quinoline (87.7 mg, 0.3 mmol) using general procedure **B** and purified by column chromatography (Heptane/ Ethyl acetate : 7/3)


¹H NMR (CDCl₃, 400MHz): 8.98–8.96 (dd, *J* = 1.6, 4.5 Hz, 1 H), 8.27–8.25 (d, *J* = 8.6 Hz, 1 H), 7.82–7.81 (dd, *J* = 7.4, 8.6 Hz, 1 H), 7.65–7.63 (m, 2 H), 7.59–7.57 (d, *J* = 7.4 Hz, 1 H), 7.43–7.39 (dd, *J* = 4.5, 8.6 Hz, 1 H), 7.34–7.31 (m, 2 H), 7.25–7.22 (m, 3 H), 3.01–2.97 (m, 2 H), 2.89–2.85 (m, 2H) ppm ;

¹³C NMR (CDCl₃, 101MHz): 150.9, 148.4, 141.2, 140.9, 135.2, 131.8, 131.3, 128.6 (2C), 128.4 (2C), 128.3, 126.2, 126.1, 125.8, 122.1, 121.4, 115.2, 36.1, 26.4 ppm ;

IR (ν , cm⁻¹): 3062, 3026, 2923, 2856, 1720, 1619, 1596, 1570, 1496, 1474, 1453, 1422, 1390, 1316, 1257, 1209, 1119, 940, 828, 801, 749, 699 ;

MS (ESI) *m/z* : 378 [M(⁷⁹Br) + H]⁺, 380 [M(⁸¹Br) + H]⁺ ;

- **5-bromo-4-(2-bromoethyl)-1-phenyl-1H-pyrazole (3m)**



M = 330.02 g/mol
C₁₁H₁₀Br₂N₂

³ S. Specklin, E. Decuypere, L. Plougastel, S. Aliani, F. Taran. *J. Org. Chem.* **2014**, 79 (16), 7772–7777

Compound **3m** was obtained in 63% yield, 65 mg (beige oil) from 3-phenyl-4-bromo-syndnone (74.7 mg, 0.31 mmol) using general procedure **C** and purified by column chromatography (Heptane/Ethyl acetate : 95/5).

¹H NMR (CDCl₃, 400MHz): δ = 7.67 (s, 1 H), 7.55–7.42 (m, 5 H), 3.55 (t, *J* = 7.4 Hz, 2 H), 3.08 (t, *J* = 7.4 Hz, 2 H) ppm ;


¹³C NMR (CDCl₃, 101MHz): δ = 140.8, 139.0, 128.9 (2C), 128.4, 125.4 (2C), 119.8, 112.9, 31.3, 28.4 ppm ;

IR (ν, cm⁻¹): 3062, 2963, 1596, 1555, 1498, 1457, 1446, 1429, 1407, 1388, 1268, 1212, 1175, 1085, 1024, 1002, 959, 912, 876, 853, 759, 715, 691, 652 ;

MS (ESI) *m/z* : 329 [M(⁷⁹Br) + H]⁺, 331 [M(⁸¹Br) + H]⁺ ;

HRMS (ESI) *m/z* calcd for C₁₁H₁₀Br₂N₂ [M+H]⁺ (⁷⁹Br): 328.9289; found: 332.89286.

- 5-{2-oxo-hexahydro-1H-thieno[3,4-d]imidazolidin-4-yl}-N-(prop-2-yn-1-yl)pentanamide.



M = 281.37 g/mol
C₁₃H₁₉N₃O₂S

Into a dried round bottom flask, ester succinimide activated biotine (341 mg, 1.0 mmol) and propargylamine (70.5 μL, 1.1 mmol) were stirred in DMF overnight at room temperature. The reaction mixture was then evaporated under vacuum, and a column chromatography was performed in AcOEt/MeOH (9/1). 273 mg of a white powder was obtained (97% yield)

Mp : 163–165 °C ;


¹H NMR (MeOD ,400MHz): δ = 4.51–4.74 (m, 1 H), 4.32–4.29 (m, 1 H), 3.94 (d, *J* = 2.9 Hz, 2 H), 3.23–3.18 (m, 1 H), 2.95–2.91 (m, 1 H), 2.72 (s, 1 H), 2.69–2.68 (m, 1 H), 2.56 (t, *J* = 2.6 Hz, 1 H), 2.22 (t, *J* = 7.5 Hz, 2 H), 1.77–1.57 (m, 6 H), 1.48–1.43 (m, 2 H) ppm ;

¹³C NMR (MeOD ,101MHz): δ = 174.4, 164.6, 79.2, 70.6, 61.9, 60.2, 55.5, 39.6, 35.0, 28.2, 27.99, 27.92, 25.2 ppm ;

IR (ν, cm⁻¹): 3285, 1689, 1637, 1541, 1465, 1322, 1263, 1158, 1062, 950, 825, 655 ;

MS (ESI) *m/z* : 304 [M+ Na]⁺.

- N-[(5-bromo-1-phenyl-1H-pyrazol-4-yl)methyl]-5-{2-methylidene-hexahydro-1H-thieno[3,4-d]imidazolidin-4-yl}pentanamide (**3n**)



M = 478.41 g/mol
C₂₀H₂₄BrN₅O₂S

Compound **3n** was obtained in 65% yield, 96 mg (white solid) from 3-phenyl-4-bromo-syndnone (74.7 mg, 0.31 mmol) using general procedure **C** and purified by column chromatography (Heptane/Ethyl acetate : 95/5).

Mp : 157–159 °C ;

¹H NMR (MeOD, 400MHz): δ = 7.74 (s, 1 H), 7.54–7.49 (m, 5 H), 4.47 (dd, J = 4.9, 7.9 Hz, 1 H), 4.32–4.27 (m, 3 H), 3.19 (ddd, J = 4.5, 5.9, 8.9 Hz, 1 H), 2.91 (dd, J = 4.9, 12.6 Hz, 1 H), 2.69 (d, J = 12.6 Hz, 1 H), 2.25 (t, J = 7.3 Hz, 2 H), 1.770–1.40 (m, 6 H) ppm ;


¹³C NMR (CDCl₃, 101MHz): δ = 174.4, 164.6, 140.8, 136.7, 128.8 (2C), 125.5 (2C), 120.0, 113.5, 61.9, 60.1, 55.5, 39.6, 35.1, 33.3, 28.3, 28.0, 25.4, 7.8 ppm ;

IR (ν , cm⁻¹) : 3287, 1695, 1664, 1629, 1542, 1498, 1459, 1389, 1263, 1068, 959, 756, 692.

MS (ESI) m/z : 478 [M(⁷⁹Br) + H]⁺, 480 [M(⁸¹Br) + H]⁺ ;

HRMS (ESI) m/z calcd for C₂₀H₂₅BrN₅O₂S [M+H]⁺ (⁷⁹Br): 478.0912; found: 478.0905.

- 5-bromo-1-phenyl-1H-pyrazol-4-yl-2-{4-[(5-chloro-3-fluoropyridin-2-yl)oxy]phenoxy} propanoate (**3o**)



Compound **3o** was obtained in 55% yield, 94 mg (yellow oil) from 3-phenyl-4-bromo-sydnone (74.7 mg, 0.31 mmol) using general procedure **C** and purified by column chromatography (Heptan/ Ethyl acetate : 95/5).

¹H NMR (CDCl₃, 400MHz): δ = 7.83 (d, J = 2.2 Hz, 1 H), 7.73 (s, 1 H), 7.54–7.41 (m, 6 H), 7.06–7.02 (m, 2 H), 6.91–6.87 (m, 2 H), 5.12 (ABq, $\Delta\delta_{AB}$ = 0.03, J_{AB} = 12.6 Hz, 2 H), 4.77 (q, J = 6.8 Hz, 1 H), 1.64 (d, J = 6.8 Hz, 3 H) ppm ;


¹³C NMR (CDCl₃, 101MHz): δ = 168.8, 151.7, 148.2 (d, J = 11.6 Hz), 143.9, 143.8 (d, J = 266.8 Hz), 138.7, 136.9 (d, J = 6.2 Hz), 135.7, 125.8 (2C), 125.6, 122.4 (2C), 121.8 (d, J = 3.8 Hz), 121.7, 119.2 (2 C), 114.1, 112.9 (2C), 111.8, 69.9, 54.7, 15.4 ppm ;

IR (ν , cm⁻¹): 1752, 1734, 1688, 1597, 1576, 1556, 1530, 1500, 1445, 1412, 1288, 1272, 1235, 1193, 1157, 1128, 1091, 1040, 1009, 953, 927, 886, 862, 843, 760, 734, 692, 650 ;

MS (ESI) m/z : 546 [M(⁷⁹Br) + H]⁺, 548 [M(⁸¹Br) + H]⁺ ;

HRMS (ESI) m/z calcd for C₂₄H₁₈BrClFN₃O₄ [M+H]⁺ (⁷⁹Br): 546.0231; found: 546.0233.

- N-[(5-bromo-1-phenyl-1H-pyrazol-4-yl)methyl]-5-(dimethylamino)naphthalene-1-sulfonamide (**3p**)



Compound **3p** was obtained in 52% yield, 78 mg (bright green solid) from 3-phenyl-4-bromo-sydnone (74.7 mg, 0.31 mmol) using general procedure **C** and purified by column chromatography (Heptane/ Ethyl acetate : 95/5).


Mp : 121–123 °C ;

¹H NMR (CDCl₃, 400MHz): δ = 8.51 (d, J = 8.6 Hz, 1 H), 8.28 (dd, J = 7.5, 1.2 Hz, 1 H), 8.24 (d, J = 8.6 Hz, 1 H), 7.58–7.49 (m, 2 H), 7.43–7.39 (m, 3 H), 7.29–7.27 (m, 2 H), 7.22 (s, 1 H), 7.16 (d, J = 7.5 Hz, 1 H), 4.99 (t, J = 6.1 Hz, 1 H), 4.06 (d, J = 6.1 Hz, 2 H), 2.83 (s, 6 H) ppm ;

¹³C NMR (CDCl₃, 101MHz): δ = 151.9, 140.7, 138.5, 134.6, 130.6, 129.8, 129.7, 129.5, 128.8 (2C), 128.45, 128.38, 125.3 (2C), 123.0, 118.5, 117.8, 115.1, 112.9, 53.4, 45.2, 37.8 ppm ;
IR (ν, cm⁻¹): 1575, 1501, 1395, 1338, 1313, 1141, 1093, 1056, 969, 942, 856, 797, 757, 698, 650.
MS (ESI) *m/z* : 486 [M(⁷⁹Br) + H]⁺, 488 [M(⁸¹Br) + H]⁺ ;
HRMS (ESI) *m/z* calcd for C₂₂H₂₁BrN₄O₂S [M+H]⁺ (⁷⁹Br): 485.0647; found: 485.0663.

Optimization of Suzuki coupling on 5-bromopyrazoles

Table S1. Suzuki coupling of bromopyrazole **3** with boronic acids.^a



Entry	Catalyst	Base	Conditions	6 (%) ^b	5 (%) ^b
1	Pd(PPh ₃) ₄	K ₃ PO ₄	Dioxane/H ₂ O (1/1) -100°C	50	50
2	Pd ₂ dba ₃ / P(cyhexyl) ₃	K ₃ PO ₄	Dioxane/H ₂ O (1/1) - 100°C	60	40
3	Pd(OAc) ₂ / XPhos	K ₃ PO ₄	MeCN /H ₂ O (1/1)- 60 °C	42	58
4	Pd(OAc) ₂ / SPhosG2	K ₃ PO ₄	Dioxane/H ₂ O (1/1) - 100°C	67	33
5	Pd(dbpf)Cl₂	K₂CO₃	MeCN /H₂O (1/1)- 60°C	75	25
7	Pd(dbpf)Cl ₂	K ₂ CO ₃	MeCN /H ₂ O (1/1)- 25°C	0	40

^areactions were conducted at 0.1M using 1 equiv. of reactant, 10% mol of Pd and 1.5 equiv. of base.


^bLCMS yields

Procedure and analytical data of 1,4,5-trisubstituted Pyrazoles

General Procedure D:

In a screw cap tube, bromopyrazole (1 equiv.), phenylboronic acid (1.2 equiv.), Pd(dtbpf)Cl₂ (0.1 equiv.) and K₂CO₃ (1.5 equiv.), were added in acetonitrile/water (1/1, 0.1 M). The reaction mixture was stirred at 100 °C overnight, then filtered on celite and washed with ethyl acetate. The filtrate was then washed with brine. The organic layer were collected, dried over anhydrous magnesium sulfate and evaporated under vacuum. The crude mixture was purified by column chromatography.

- 1-(4-methylphenyl)-5-phenyl-4-(2-phenylethyl)-1H-pyrazole (**6a**)



M = 338.45 g/mol
C₂₄H₂₂N₂

Compound **6a** was obtained with 41 mg, **75%** yield (bright yellow solid) from **3b** (55 mg, 0.16 mmol) and phenylboronic acid (24 mg, 0.20 mmol) using general procedure **D** and purified by column chromatography (Heptane/Ethyl acetate : 95/05).

Mp : 119–121 °C


¹H NMR (CDCl₃, 400MHz): δ = 7.61 (s, 1 H), 7.32–7.05 (m, 14 H), 2.89–2.77 (m, 4 H), 2.31 (s, 3 H) ppm ;

¹³C NMR (CDCl₃, 101MHz): δ = 141.6, 139.9, 139.8, 137.8, 136.5, 130.7, 129.9 (2C), 129.2 (2C), 128.5 (2C), 128.4 (2C), 128.3 (2C), 128.0, 125.9, 124.4 (2C), 120.7, 31.1, 26.0, 21.0 ppm ;

IR (ν, cm⁻¹): 3027, 2921, 2857, 1604, 1516, 1496, 1444, 1454, 1384, 1090, 1071, 964, 819, 772, 697, 659, 583, 551, 515 ;

MS (ESI) *m/z* : 339 [M + H]⁺ .

- 1-(4-methylphenyl)-5-[(E)-2-phenylethenyl]-4-(2-phenylethyl)-1H-pyrazole (**6b**)



M = 364.49 g/mol
C₂₆H₂₄N₂

Compound **6b** was obtained in 38 mg, **66%** yield (bright yellow solid) from **3b** (55 mg, 0.16 mmol) and vinylphenylboronic acid (30 mg, 0.20 mmol) using general procedure **D** and purified by column chromatography (Heptane/Ethyl acetate : 95/05).

Mp: 114–116 °C

¹H NMR (CDCl₃, 400MHz): δ = 7.55 (s, 1 H), 7.39–7.21 (m, 14 H), 6.85–6.72 (m, 2 H), 3.06–2.97 (m, 4 H), 2.42 (s, 3 H) ppm ;


¹³C NMR (CDCl₃, 101MHz): δ = 141.6, 140.1, 137.7, 137.5, 136.9, 136.8, 132.1, 129.7 (2C), 128.7 (2C), 128.5 (2C), 128.4 (2C), 128.1, 126.4 (2C), 126.1, 125.0 (2C), 120.1, 116.6, 36.6, 27.2, 21.1 ppm ;

IR (ν, cm⁻¹): 3026, 2923, 2859, 1603, 1516, 1496, 1454, 1390, 1089, 970, 822, 750, 697, 508 ;

MS (ESI) *m/z* : 365 [M + H]⁺ ;

HRMS (ESI) *m/z* calcd for C₂₆H₂₄N₂ [M+H]⁺ : 365.2018; found: 365.2020.

- 5-cyclopropyl-1-(4-methylphenyl)-4-(2-phenylethyl)-1H-pyrazole (**6c**)



M = 302.42 g/mol
C₂₁H₂₂N₂

Compound **6c** was obtained in 54% yield, 26 mg (red oil) from **3b** (55 mg, 0.16 mmol) and cyclopropylboronic acid (16 mg, 0.19 mmol) using general procedure **D** and purified by column chromatography (Heptane/Ethyl acetate : 95/05).

¹H NMR (CDCl₃, 400MHz): δ = 7.44 (s, 1 H), 7.40 (d, *J* = 8.3 Hz, 2 H), 7.33–7.29 (m, 2 H), 7.24–7.22 (m, 5 H), 2.95–2.91 (m, 2 H), 2.86–2.82 (m, 2 H), 2.41 (s, 3 H), 1.61–1.54 (m, 1 H), 0.79–0.75 (m, 2 H), 0.41–0.37 (m, 2 H) ppm ;


¹³C NMR (CDCl₃, 101MHz): δ = 141.89, 139.8, 139.4, 138.0, 136.7, 129.1 (2C), 128.5 (2C), 128.3 (2C), 125.1, 124.4 (2C), 120.9, 37.2, 26.2, 21.0, 6.6 (2C), 5.9 ppm ;

IR (ν, cm⁻¹): 3025, 2922, 2857, 1720, 1603, 1516, 1496, 1453, 1386, 1207, 1091, 1029, 976, 904, 818, 729, 698, 660 ;

MS (ESI) *m/z* : 303 [M + H]⁺ ;

HRMS (ESI) *m/z* calcd for C₂₁H₂₂N₂ [M+H]⁺ : 303.1861; found: 303.1868.

- 1-(4-fluorophenyl)-5-phenyl-4-(2-phenylethyl)-1H-pyrazole (**6d**)



Compound **6d** was obtained in 75% yield, 37 mg (bright yellow solid) from **3d** (50 mg, 0.14 mmol) and phenylboronic acid (21 mg, 0.17 mmol) using general procedure **D** and purified by column chromatography (Heptane/Ethyl acetate : 95/05).

Mp : 114–116 °C

¹H NMR (CDCl₃, 400MHz): δ = 7.60 (s, 1 H), 7.33–7.31 (m, 3 H), 7.27–7.24 (m, 2 H), 7.20–7.15 (m, 3 H), 7.12–7.10 (m, 2 H), 7.06–7.03 (m, 2 H), 6.97–6.93 (m, 2 H), 2.88–2.84 (m, 2 H), 2.80–2.76 (m, 2 H) ppm ;


¹³C NMR CDCl₃, 101MHz): δ = 161.2 (d, *J*_{C-F} = 247 Hz, 1C), 141.5, 140.2, 139.9, 136.3 (d, *J*_{C-F} = 3.1 Hz, 1C), 130.2, 129.8, 128.5, 128.4 (2C), 128.3 (2C), 128.2, 126.3 (d, *J*_{C-F} = 8.5 Hz, 2C), 125.9, 120.5, 115.5 (d, *J*_{C-F} = 23.1 Hz, 2C), 37.1, 25.9 ppm ;

IR (ν, cm⁻¹) : 3061, 3026, 2924, 2857, 1603, 1510, 1453, 1444, 1385, 1218, 1153, 1087, 1070, 963, 909, 836, 819, 773, 731, 696 ;

MS (ESI) *m/z* : 343 [M + H]⁺ ;

HRMS (ESI) *m/z* calcd for C₂₃H₁₉FN₂ [M+H]⁺ : 343.1611; found: 343.1607.

- tert*-butyl *N*-[(1,5-diphenyl-1H-pyrazol-4-yl)methyl]carbamate (**6e**)



Compound **6e** was obtained in 42% yield, 16 mg (red oil) from **3j** (40 mg, 0.11 mmol) and phenylboronic acid (17 mg, 0.14 mmol) using general procedure **D** and purified by column chromatography (Heptane/Ethyl acetate : 7/3).

¹H NMR (CDCl₃, 400MHz): δ = 7.77 (s, 1 H), 7.35–7.34 (m, 3 H), 7.29–7.16 (m, 7H), 4.66 (br. s, 1 H), 4.21 (d, *J* = 4.2 Hz, 2 H), 1.45 (s, 9 H) ppm ;


¹³C NMR (CDCl₃, 101MHz): δ = 155.5, 140.4, 140.2, 139.8, 129.8 (2C), 129.5, 128.7 (2C), 127.1, 124.7 (2C), 118.7, 79.6, 34.9, 28.3 (3C) ppm ;

IR (ν, cm⁻¹): 3334, 3056, 2976, 2930, 1693, 1597, 1503, 118, 1384, 1365, 1268, 1248, 1165, 1069, 1046, 1021, 963, 914, 864, 772, 762, 736, 698 ;

MS (ESI) *m/z* 350 [M + H]⁺ ;

HRMS (ESI) *m/z* calcd for C₂₁H₂₃N₃O₂ [M+H]⁺ : 350.1869; found: 350.1860.

- 5-(dimethylamino)-N-[(1,5-diphenyl-1H-pyrazol-4-yl)methyl]naphthalene-1-sulfonamide (**6f**)



M = 482.60 g/mol
C₂₈H₂₆N₄O₂S

Compound **6f** was obtained with 55 % yield, 40 mg (bright yellow solid) from **3p** (74 mg, 0.15 mmol) and phenylboronic acid (22 mg, 0.18 mmol) using general procedure **D** and purified by column chromatography (Heptane/Ethyl acetate : 7/3).

Mp : 181–183 °C ;

¹H NMR (CDCl₃, 400MHz): δ = 8.55–8.53 (d, *J* = 8.3 Hz, 1 H), 8.24–8.20 (m, 2 H), 7.57–7.53 (dd, *J* = 8.3 Hz, 8.2 Hz, 1 H), 7.51–7.47 (dd, *J* = 8.0 Hz, 7.7 Hz, 1 H), 7.36 (s, 1 H), 7.24–7.20 (m, 5 H), 7.11–7.05 (m, 4 H), 6.86 (d, *J* = 7.2 Hz, 2 H), 4.72–4.70 (t, *J* = 5.7 Hz, 1 H), 4.00–3.97 (d, *J* = 5.7 Hz, 2 H), 2.90 (s, 6 H) ppm ;


¹³C NMR CDCl₃, 101MHz): δ = 140.8, 140.3, 139.5, 134.2, 130.6, 129.9, 129.8, 129.5, 129.4 (2C), 128.7, 128.6 (2C), 128.5, 128.48 (2C), 128.43, 127.2, 124.7 (2C), 123.1, 118.6, 116.2, 115.9, 115.1, 45.4 (2C), 37.7 ppm ;

IR (ν, cm⁻¹): 1574, 1504, 1450, 1385, 1329, 1229, 1161, 1141, 1060, 962, 948, 836, 785, 696, 624 ;

MS (ESI) *m/z* : 483 [M + H]⁺ ;

HRMS (ESI) *m/z* calcd for C₂₈H₂₆N₄O₂S [M+H]⁺ : 483.1855; found: 483.1855.

- N-[(1,5-diphenyl-1H-pyrazol-4-yl)methyl]-5-[2-methylidene-hexahydro-1H-thieno[3,4-d]imidazolidin-4-yl]pentanamide (**6g**)



M = 475.61 g/mol
C₂₆H₂₉N₅O₂S

Compound **6g** was obtained in 34% yield, 25 mg (white oil) from **3n** (75 mg, 0.16 mmol) and phenylboronic acid (23 mg, 0.19 mmol) using general procedure **D** and purified by column chromatography (Ethyl acetate/Methanol : 9/1).

¹H NMR (MeOD, 400MHz): δ = 8.42 (br. s, 2 H), 7.77 (s, 1 H), 7.38–7.30 (m, 6 H), 7.25–7.19 (m, 4 H), 4.49–4.46 (m, 1 H), 4.30–4.27 (m, 1 H), 4.25 (d, *J* = 1.9 Hz, 2 H), 3.21–3.16 (m, 1 H), 2.92 (dd, *J* = 5.0, 13 Hz, 1 H), 2.71–2.68 (d, *J* = 13 Hz, 1 H), 2.19 (t, *J* = 7.3 Hz, 2 H), 1.77–1.54 (m, 6 H), 1.45–1.37 (m, 2 H) ppm ;


¹³C NMR (MeOD, 101MHz): δ = 174.3, 164.6, 141.1, 140.0, 139.5, 129.7 (2C), 129.2, 128.5 (2C), 128.4, 128.3 (2C), 127.4, 125.0 (2C), 118.2, 61.9, 60.2, 55.5, 39.6, 35.1, 33.1, 28.3, 28.0, 25.3 ppm ;

IR (ν, cm⁻¹): 3357, 2479, 2242, 2071, 1671, 1451, 119, 972, 822 ;





MS (ESI) *m/z* : 476 [M + H]⁺ ;


HRMS (ESI) *m/z* calcd for C₂₆H₂₉N₅O₂S [M+H]⁺ : 476.2120 ; found: 476.2118.

Mechanism study of the CuSAC reaction




This experiment was conducted with procedure B in deuterated solvents.










	M+1	M+2 (1D)	M+3 (2D)	M+4 (3D)	M+5 (4D)	M+6 (5D)
	263	264	265	266	267	268
area tot	1274248	13968427	5780796	912161		
Σ contrib	0	262495	2848907	878088	65657	-12844
area D	0	13705932	2931889	34073	-65657	12844
% D	0	76,6%	16,4%	0,2%	-0,4%	0,1%




This experiment was conducted with procedure B using deuterated solvents.








	M+1	M+2 (1D)	M+3 (2D)	M+4 (3D)	M+5 (4D)	M+6 (5D)
	341	342	343	344	345	346
area tot	452107	10438404	2513561	10107113	2025830	209610
Σ contrib	0	92230	2557301	10304377	2005435	-199568
area D	0	10346174	-43740	-197264	20395	409178
% D	0	97,3%	-0,4%	-1,9%	0,2%	3,8%

NMR spectra of Imidazoquinoxalines










ppm


135,739
132,683
126,358
124,377
116,581
112,192





L9




















NMR spectra of Pyrazoles


ppm
7,553
7,549
7,544
7,529
7,520
7,500
7,495
7,482
7,478
7,466
7,463
7,437
7,433
7,430
7,421
7,415
7,409
7,397
7,334
7,330
7,321
7,315
7,314
7,305
7,297
7,262
7,243
7,226
7,211
7,208


2,944
2,927
2,920
2,905
2,825
2,810
2,803
2,787
2,784





ppm
9
8,5
8
7,5
7
6,5
6
5,5
5
4,5
4
3,5
3
2,5
2
1,5
1
0,5
0





































































































































ppm

